- 1、本文档共43页,可阅读全部内容。
- 2、原创力文档(book118)网站文档一经付费(服务费),不意味着购买了该文档的版权,仅供个人/单位学习、研究之用,不得用于商业用途,未经授权,严禁复制、发行、汇编、翻译或者网络传播等,侵权必究。
- 3、本站所有内容均由合作方或网友上传,本站不对文档的完整性、权威性及其观点立场正确性做任何保证或承诺!文档内容仅供研究参考,付费前请自行鉴别。如您付费,意味着您自己接受本站规则且自行承担风险,本站不退款、不进行额外附加服务;查看《如何避免下载的几个坑》。如果您已付费下载过本站文档,您可以点击 这里二次下载。
- 4、如文档侵犯商业秘密、侵犯著作权、侵犯人身权等,请点击“版权申诉”(推荐),也可以打举报电话:400-050-0827(电话支持时间:9:00-18:30)。
查看更多
Meet AZN management:
American Society of
Clinical Oncology
(ASCO) Cancers
Symposium 2022
For investors and analysts
6 June 2022
Forward-looking statements
In order, among other things, to utilise the safe harbour provisions of the US Private Securities Litigation Reform Act of 1995, AstraZeneca (hereafter ‘the Group’) provides the
following cautionary statement: this document contains certain forward-looking statements with respect to the operations, performance and financial condition of the Group,
including, among other things, statements about expected revenues, margins, earnings per share or other financial or other measures. Although the Group believes its expectations
are based on reasonable assumptions, any forward-looking statements, by their very nature, involve risks and uncertainties and may be influenced by factors that could cause actual
outcomes and results to be materially different from those predicted. The forward-looking statements reflect knowledge and information available at the date of preparation of this
document and the Group undertakes no obligation to update these forward-looking statements. The Group identifies the forward-looking statements by using the words
anticipates, believes, expects, intends and similar expressions in such statements. Important factors that could cause actual results to differ materially from those contained in
forward-looking statements, certain of which are beyond the Group’s control, include, among other things: the risk of failure or delay in delivery of pipeline or launch of new
medicines; the risk of failure to meet regulatory or ethical requirements for medicine development or approval; the risk of failure to obtain, defend and enforce effective IP
protection and IP challenges by third parties; the impact of competitive pressures including expiry or l
您可能关注的文档
- 2022年第38届几何学计算国际研讨会(会议论文合集).pdf
- 2022年第49届EATCS自动机、语言和编程国际会议(会议论文合集).pdf
- 经济事务研究所-碳难题:如何从政府失败中拯救气候变化政策(英)-2022.8.pdf
- 2022年全球项目风险报告.pdf
- 2022年施工风险管理报告.pdf
- 2022施耐德电气铁路云峰会:绿色、智能——施耐德电气创新未来开关设备.pdf
- EY 上市指南:上市前、上市中和上市后的战略考虑.pdf
- SAP 如何通过数字化转型提升采购部门的价值(中文).pdf
- 阿斯利康 2022年泌尿生殖系统癌症研讨会演示资料.pdf
- 百时美施贵宝 疾病状态信息图表合集.pdf
- 同位素在判断地下水来源方向中的应用研究.pptx
- 鱼脊型水石分离系统对漂木减灾效果的实验研究.pptx
- 基于多频信息的城市水下特长隧道中部光环境优化设计.pptx
- 图像分割方法的仔猪保育箱温度适宜性监测.pptx
- 岩土工程勘察土工试验中常见问题与处理方法.pptx
- 钻爆法施工隧道噪声传播特性研究.pptx
- 教师成长动力的生成基于问题解决的学习与共同学习.pptx
- 河北承德大庙杂岩体成矿规律研究及远景预测.pptx
- 2024江西中医药大学附属医院中医住院医师规范化培训对象招生65人笔试备考试题及答案解析.docx
- 2024广东中山大学附属第五医院病理科技师岗位招聘1人笔试备考题库及答案解析.docx
文档评论(0)